$2.21
2.31% today
Nasdaq, Apr 02, 10:00 pm CET
ISIN
US56600D1072
Symbol
MRVI

Maravai LifeSciences Target price 2025 - Analyst rating & recommendation

Maravai LifeSciences Classifications & Recommendation:

Buy
47%
Hold
47%
Sell
7%

Maravai LifeSciences Price Target

Target Price $5.27
Price $2.21
Potential
Number of Estimates 11
11 Analysts have issued a price target Maravai LifeSciences 2026 . The average Maravai LifeSciences target price is $5.27. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 15 analysts: 7 Analysts recommend Maravai LifeSciences to buy, 7 to hold and 1 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Maravai LifeSciences stock has an average upside potential 2026 of . Most analysts recommend the Maravai LifeSciences stock at Buy or hold.

Sales and Margin forecast 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 259.19 192.93
10.30% 25.56%
EBITDA Margin -2.40% -8.05%
115.53% 235.99%
Net Margin -57.52% -47.83%
30.06% 16.84%

15 Analysts have issued a sales forecast Maravai LifeSciences 2025 . The average Maravai LifeSciences sales estimate is

$193m
Unlock
. This is
25.56% lower
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$212m 18.17%
Unlock
, the lowest is
$185m 28.62%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $259m 10.30%
2025
$193m 25.56%
Unlock
2026
$215m 11.28%
Unlock
2027
$270m 25.84%
Unlock
2028
$303m 12.12%
Unlock
2029
$251m 17.06%
Unlock

15 Analysts have issued an Maravai LifeSciences EBITDA forecast 2025. The average Maravai LifeSciences EBITDA estimate is

$-15.5m
Unlock
. This is
38.82% lower
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$9.0m 180.43%
Unlock
, the lowest is
$-39.0m 248.53%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $-6.2m 113.93%
2025
$-15.5m 150.14%
Unlock
2026
$1.1m 107.37%
Unlock
2027
$31.9m 2,685.91%
Unlock
2028
$4.1m 87.15%
Unlock
2029
$10.5m 156.10%
Unlock

EBITDA Margin

2024 -2.40% 115.53%
2025
-8.05% 235.99%
Unlock
2026
0.53% 106.58%
Unlock
2027
11.81% 2,128.30%
Unlock
2028
1.35% 88.57%
Unlock
2029
4.18% 209.63%
Unlock

3 Maravai LifeSciences Analysts have issued a net profit forecast 2025. The average Maravai LifeSciences net profit estimate is

$-92.3m
Unlock
. This is
36.89% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-63.9m 56.31%
Unlock
, the lowest is
$-126m 13.59%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $-149m 16.67%
2025
$-92.3m 38.09%
Unlock
2026
$-40.1m 56.58%
Unlock
2027
$-33.6m 16.22%
Unlock
2028
$-69.6m 107.24%
Unlock
2029
$-68.2m 2.04%
Unlock

Net Margin

2024 -57.52% 30.06%
2025
-47.83% 16.84%
Unlock
2026
-18.67% 60.97%
Unlock
2027
-12.42% 33.48%
Unlock
2028
-22.97% 84.94%
Unlock
2029
-27.12% 18.07%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ -1.05 -0.65
16.67% 38.10%
P/E negative
EV/Sales 3.20

3 Analysts have issued a Maravai LifeSciences forecast for earnings per share. The average Maravai LifeSciences EPS is

$-0.65
Unlock
. This is
36.89% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$-0.45 56.31%
Unlock
, the lowest is
$-0.89 13.59%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-1.05 16.67%
2025
$-0.65 38.10%
Unlock
2026
$-0.28 56.92%
Unlock
2027
$-0.24 14.29%
Unlock
2028
$-0.49 104.17%
Unlock
2029
$-0.48 2.04%
Unlock

P/E ratio

Current -2.09 78.27%
2025
-3.32 58.85%
Unlock
2026
-7.65 130.42%
Unlock
2027
-9.14 19.48%
Unlock
2028
-4.41 51.75%
Unlock
2029
-4.50 2.04%
Unlock

Based on analysts' sales estimates for 2025, the Maravai LifeSciences stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 2.38 55.84%
2025
3.20 34.26%
Unlock
2026
2.87 10.13%
Unlock
2027
2.28 20.54%
Unlock
2028
2.04 10.81%
Unlock
2029
2.45 20.56%
Unlock

P/S ratio

Current 1.20 69.84%
2025
1.61 34.34%
Unlock
2026
1.45 10.13%
Unlock
2027
1.15 20.54%
Unlock
2028
1.02 10.81%
Unlock
2029
1.24 20.57%
Unlock

Current Maravai LifeSciences Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
Morgan Stanley
Locked
Locked
Locked Mar 25 2025
UBS
Locked
Locked
Locked Mar 21 2025
B of A Securities
Locked
Locked
Locked Mar 03 2025
Baird
Locked
Locked
Locked Feb 26 2025
Goldman Sachs
Locked
Locked
Locked Dec 05 2024
Wolfe Research
Locked
Locked
Locked Nov 14 2024
Baird
Locked
Locked
Locked Nov 08 2024
Analyst Rating Date
Locked
Morgan Stanley:
Locked
Locked
Mar 25 2025
Locked
UBS:
Locked
Locked
Mar 21 2025
Locked
B of A Securities:
Locked
Locked
Mar 03 2025
Locked
Baird:
Locked
Locked
Feb 26 2025
Locked
Goldman Sachs:
Locked
Locked
Dec 05 2024
Locked
Wolfe Research:
Locked
Locked
Nov 14 2024
Locked
Baird:
Locked
Locked
Nov 08 2024

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today